-
V341165-100mgEndogenous cannabinoid receptor mixed antagonist/agonist found in higher concentrations peripherally than anandamide. Full agonist at GPR55 and CB2 and partial antagonist/agonist at CB1 (EC|50|values are 12, 381 and 2920 nM at GPR55, CB2 and CB1
-
V341165-10mgEndogenous cannabinoid receptor mixed antagonist/agonist found in higher concentrations peripherally than anandamide. Full agonist at GPR55 and CB2 and partial antagonist/agonist at CB1 (EC|50|values are 12, 381 and 2920 nM at GPR55, CB2 and CB1
-
V341165-25mgEndogenous cannabinoid receptor mixed antagonist/agonist found in higher concentrations peripherally than anandamide. Full agonist at GPR55 and CB2 and partial antagonist/agonist at CB1 (EC|50|values are 12, 381 and 2920 nM at GPR55, CB2 and CB1
-
V341165-50mgEndogenous cannabinoid receptor mixed antagonist/agonist found in higher concentrations peripherally than anandamide. Full agonist at GPR55 and CB2 and partial antagonist/agonist at CB1 (EC|50|values are 12, 381 and 2920 nM at GPR55, CB2 and CB1
-
V341165-5mgEndogenous cannabinoid receptor mixed antagonist/agonist found in higher concentrations peripherally than anandamide. Full agonist at GPR55 and CB2 and partial antagonist/agonist at CB1 (EC|50|values are 12, 381 and 2920 nM at GPR55, CB2 and CB1
-
-
-
V649212-1mgVomifoliol, a compound related to abscisie acid (ABA), has a modified 2,4-pentadiene side chain and has activity equal to that displayed by ABA. Vomifoliol exhibits antiacetylcholinesterase activity and displays moderate antileishmanial
-
V649212-5mgVomifoliol, a compound related to abscisie acid (ABA), has a modified 2,4-pentadiene side chain and has activity equal to that displayed by ABA. Vomifoliol exhibits antiacetylcholinesterase activity and displays moderate antileishmanial
-
-
-